Annotation Detail

Information
Associated Genes
MAP2K1
Associated Variants
MAP2K1 MUTATION
MAP2K1 MUTATION
Associated Disease
Malignant neoplasm of thyroid
Source Database
DisGeNET
Description
To investigate this, we used mass spectrometry to complete a global phosphoproteomic analysis of a BRAFV600E thyroid cancer cell line (SW1736) after treatment with the mutation-selective inhibitor vemurafenib (PLX4032) and MEK1/2 inhibitor selumetinib (AZD6244).
Pubmed
24825855
Section of the abstract supporting the evidence
ALL_TEXT_2/3
Number of the section of the abstract supporting the evidence
2
Number of the sentence supporting the evidence
4
Original source reporting the Gene Disease association
BeFree
DisGENET score for the Gene Disease association
0.00108576748832121
Drugs